Miquel Vila Bover

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

Instituciones de las que forman parte

Jefe de grupo
Enfermedades Neurodegenerativas

Vall Hebron Institut de Recerca

Miquel Vila Bover

Instituciones de las que forman parte

Jefe de grupo
Enfermedades Neurodegenerativas

Vall Hebron Institut de Recerca

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder.

In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN).

I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.

Proyectos

Modulation of age-dependent neuromelanin accumulation as a novel therapeutic strategy for Parkinson’s disease and brain aging

IP: Miquel Vila Bover
Colaboradores: Ariadna Laguna Tuset, Thais Cuadros Arasa, Marta González Sepúlveda, Annabelle Parent
Entidad financiadora: Fundació "La Caixa"
Financiación: 466004
Referencia: FBLC/HR17-00513/VILA
Duración: 01/09/2018 - 05/01/2022

ROL DE LA NEUROMELANINA EN LA ENFERMEDAD DE PARKINSON Y EL ENVEJECIMIENTO CEREBRAL: ESTUDIO DEL POTENCIAL TERAPEUTICO EN NUEVOS MODELOS PRECLINICOS "HUMANIZADOS" IN VIVO

IP: Miquel Vila Bover
Colaboradores: Miriam Izquierdo Sans
Entidad financiadora: Ministerio Economía, Industria y Competitividad
Financiación: 96843.15
Referencia: BES-2017-080191
Duración: 01/07/2018 - 30/11/2022

Lewy body extracts from parkinson's disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys

IP: Miquel Vila Bover
Colaboradores: -
Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca
Financiación: 35200
Referencia: 2017SGR1806
Duración: 01/01/2017 - 30/09/2021

Rol de la neuromelanina en la enfermedad de Parkinson y del envejecimiento cerebral: estudio `ptemcoañ terpéutico en nuevos modelos preclínicos "humanizados" in vivo.

IP: Miquel Vila Bover
Colaboradores: Ariadna Laguna Tuset, Thais Cuadros Arasa
Entidad financiadora: Ministerio Economía, Industria y Competitividad
Financiación: 363000
Referencia: SAF2016-77541-R
Duración: 30/12/2016 - 29/12/2020